China Resources Jiangzhong Pharmaceutical Co.,Ltd (SHA:600750)
22.14
-0.31 (-1.38%)
Sep 24, 2026, 3:00 PM CST
SHA:600750 Revenue
China Resources Jiangzhong Pharmaceutical Co.,Ltd had revenue of 896.12M CNY in the quarter ending June 30, 2026, a decrease of -6.36%. This brings the company's revenue in the last twelve months to 4.01B, down -6.81% year-over-year. In the year 2025, China Resources Jiangzhong Pharmaceutical Co.,Ltd had annual revenue of 4.22B, down -4.87%.
Revenue (ttm)
4.01B
Revenue Growth
-6.81%
P/S Ratio
3.47
Revenue / Employee
921.57K
Employees
4,352
Market Cap
13.94B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.22B | -215.95M | -4.87% |
| Dec 31, 2024 | 4.44B | -117.76M | -2.59% |
| Dec 31, 2023 | 4.55B | 668.03M | 17.19% |
| Dec 31, 2022 | 3.89B | 1.01B | 35.19% |
| Dec 31, 2021 | 2.87B | 432.52M | 17.72% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shandong Buchang Pharmaceuticals | 11.21B |
| Zhejiang Hisun Pharmaceutical | 9.77B |
| Guobang Pharma | 6.13B |
| Shenzhen Hepalink Pharmaceutical Group | 5.24B |
| Zhejiang Jiuzhou Pharmaceutical | 5.21B |
| Porton Pharma Solutions | 3.59B |
| Tonghua Dongbao Pharmaceutical | 3.10B |
| Shenzhen Kangtai Biological Products | 2.55B |